On April 9, 2020, Longevity Technology interviewed AFAR expert Nir Barzilai, MD, on how targeting the biology of aging through geroprotectors can help improve immune health in older adults and prevent the severity of COVID-19. Dr. Barzilai poses that drugs such as metformin and rapamycin can lessen the severity of COVID-19 and similar viruses in the future, and he highlights the importance of the AFAR-managed TAME Trial to provide proof-of-concept that the biology of aging can be targeted through promising therapeutics.
Dr. Barzilai is AFAR’s Scientific Director, a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award winner, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Dr. Barzilai also presented on the potential of metformin in the fight against COVID-19 and the overall benefits of the upcoming TAME Trials in our recent AFAR webinar, “COVID-19: Can the Science of Aging move us Forward?”
Read the article, “COVID-19: Leading clinician calls for focus on the biology of aging,” here.
Watch Dr. Barzilai’s presentation from our recent AFAR webinar here. Watch clips from all the presenters here.
Learn more about the TAME Trial here.
